Novacyt and Illumina sign five-year collaboration framework

Novacyt and Illumina have entered into a five-year master collaboration agreement to explore molecular-diagnostics product development and commercial opportunities.

The agreement creates a framework for the companies to combine Novacyt's molecular-diagnostics capabilities with Illumina's sequencing and array technologies across potential future projects.

The collaboration is an enabling framework rather than a commitment to a single product programme, with individual projects expected to require separate agreements.

Field	Content
Alert Type	Industry Update
Companies	Novacyt; Illumina
Agreement Type	Master collaboration agreement
Agreement Term	Five years
Sector	Molecular diagnostics; genomics
Technology or Modality	Molecular diagnostics, DNA sequencing and array technologies
Geography	Global
What Happened	Novacyt and Illumina entered into a five-year master collaboration agreement to explore future product-development and commercial opportunities.
Why It Matters	The framework links Novacyt's molecular-diagnostics capabilities with Illumina's sequencing and array technologies.
Supporting Context	Specific projects arising from the framework are expected to be governed by separate agreements.
Potential Impact	Successful projects could broaden Novacyt's diagnostic-development capabilities and create new applications using Illumina technologies.
Key Takeaway	Novacyt and Illumina have established a five-year framework for potential molecular-diagnostics collaboration.
What to Watch	Announcement of specific projects or commercial programmes under the collaboration.
Primary Source	Novacyt
Relevant Date	1 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com